AbCellera Biologics Newsroom

Earnings Preview: ABCL to Report Financial Results Post-market on November 04

$AbCellera Biologics(ABCL.US)$ is scheduled to release its financial results post-market on November 04 ET. Earnings PreviewAnalysts estimate $AbCellera Biologics(ABCL.US)$ to post revenue of USD8.01

Futu NewsOct 30 09:00

CORRECTION: Abacus Life Ticker Is 'ABL'

BenzingaOct 22 20:28

Abacus Life Sees Prelim. Q3 Total Revenue $26M-$28M Vs $29.256M Est.

BenzingaOct 22 20:16

We Think AbCellera Biologics (NASDAQ:ABCL) Needs To Drive Business Growth Carefully

Simply Wall StOct 18 21:24

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

BusinesswireOct 4 21:00

Press Release: AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Dow JonesSep 27 04:06

Carl Hansen Buys Handful Of Shares In AbCellera Biologics

Yahoo FinanceAug 31 20:13

AbCellera to Present at Upcoming Investor Conferences in September

newsfilter.ioAug 30 04:05

AbCellera Biologics Inc. (ABCL): A Top Contender Among Canada's Best Penny Stocks in 2024

Yahoo FinanceAug 29 17:13

KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating

KeyBanc analyst Scott Schoenhaus maintains $AbCellera Biologics(ABCL.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.7% and a total average return of -2.9%

Futu NewsAug 23 15:31 · Ratings

KeyBanc Keeps Their Buy Rating on AbCellera Biologics (ABCL)

TipRanksAug 23 15:15

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

BenzingaAug 20 21:45

Benchmark Co. Downgrades AbCellera Biologics(ABCL.US) to Hold Rating

Benchmark Co. analyst Robert Wasserman downgrades $AbCellera Biologics(ABCL.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 41.5% and a total average return of 8.3%

Futu NewsAug 20 19:33 · Ratings

Express News | Abcellera Biologics Inc : Benchmark Cuts to Hold Rating

BreakingsAug 20 18:06

Need To Know: The Consensus Just Cut Its AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates For 2024

Yahoo FinanceAug 11 20:21

Earnings Update: AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Are Trimming Their Forecasts

Yahoo FinanceAug 9 18:35

Strong Liquidity and Strategic Alliances Underpin Buy Rating for AbCellera Biologics

TipRanksAug 9 17:57 · Ratings

Understanding the Buy Rating: A Synopsis of AbCellera Biologics' Investment Potential

TipRanksAug 8 21:51 · Ratings

Nvidia-backed Recursion to Acquire Exscientia in All-stock Deal

Seeking AlphaAug 8 19:54

Buy Rating Affirmed for AbCellera Biologics Amid Expanding TCE Program and Strengthened Eli Lilly Collaboration

TipRanksAug 7 19:45